CAS 12650-69-0 Mupirocin - Analytical Products / Alfa Chemistry

CAT	APS12650690
CAS	12650-69-0
MDL Number	MFCD01711620
Synonyms	Mupirocin, 9-[[(2E)-4-[(2S,3R,4R,5S)-3,4-Dihydroxy-5-[[(2S,3S)-3-[(1S,2S)-2-hydroxy-1-methylpropyl]oxiranyl]methyl]tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoyl]oxy]nonanoic acid
IUPAC Name	9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid
Molecular Weight	500.62
Molecular Formula	C26H44O9
Canonical SMILES	C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]2CO[C@@H](C\C(=C\C(=O)OCCCCCCCCC(=O)O)\C)[C@H](O)[C@@H]2O
InChI	InChI=1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1
InChI Key	MINDHVHHQZYEEK-HBBNESRFSA-N

Accurate Mass	500.2985
Format	Neat

* Products or Services Interested: Mupirocin (12650-69-0)
* Your question
* Name
* Email
Verification Code

CAT	Size	Shipping	Storage Conditions	Description	Price
APS12650690-250MG	250MG	Room Temperature	+5°C	Subcategory: Mikromol, Antibiotics, API standards, Respiratory drugs; API Family: Matrix - API Family Mupirocin Calcium; Mupirocin; Product Type: API	Inquiry
APS12650690-10MG	10MG	Room Temperature	-20°C Freezer	Subcategory: Chiral molecules, Stable isotope labelled compounds, Herbicides and metabolites	Inquiry

Case Study

Mupirocin for the Preparation of Nanofibrous Dual-Carrier Systems in Wound Healing Applications

Qadikolaei, Zahra Majidi, Sayed Mahmood Rabiee, and Adeleh Gholipour-Kanani. International Journal of Biological Macromolecules 267 (2024): 131378.

Mupirocin has been successfully incorporated into layered double hydroxide (LDH) structures and electrospun nanofibers to achieve sustained antibacterial release for wound healing. The experimental process can be summarized as follows:
1. Preparation of LDH precursor solution
Magnesium nitrate and aluminum nitrate were dissolved in deionized water in a 3:1 molar ratio (Mg²⁺:Al³⁺) to obtain a 2.5 M solution.
2. Formation of Mg-Al LDH
A 3.0 M NaOH solution was added dropwise under magnetic stirring to adjust the pH to ~10, leading to the formation of a white precipitate. The mixture was stirred for 2 h and aged at 60 °C for 24 h.
3. Purification and drying
The precipitate was repeatedly washed with deionized water and ethanol until neutral pH, then dried at 40 °C for 48 h and ground to a fine powder.
4. Mupirocin loading
For drug incorporation, mupirocin (0.03 g) was introduced directly into the metal nitrate precursor solution before co-precipitation, ensuring entrapment within the LDH layers.
5. Electrospinning of nanofibers
The mupirocin-loaded LDH was dispersed in a PVA solution at optimized ratios and electrospun under controlled voltage and flow conditions to yield bead-free nanofibers.
6. Characterization and testing
SEM confirmed uniform fiber morphology (~270 ± 58 nm). FTIR validated mupirocin-LDH interactions. Drug release studies showed ~54% release within 6 h. Antibacterial assays demonstrated efficacy against Gram-positive bacteria, while MTT confirmed biocompatibility.
This stepwise approach highlights mupirocin's potential in fabricating advanced dual-carrier nanofibrous wound dressings.

Mupirocin for the Preparation of Silk Fibroin-Based Hydrogels as Advanced Wound Dressings in Diabetic Wound Therapy

Watchararot, Tanapong, et al. Journal of Drug Delivery Science and Technology 108 (2025): 106910.

Mupirocin (MUP) is a widely prescribed topical antibiotic for the treatment of wound infections, yet its clinical application is limited by rapid degradation, tissue irritation, and the risk of resistance development. To overcome these shortcomings, a silk fibroin (SF)-based hydrogel system was engineered to encapsulate and sustain the release of MUP for diabetic wound management.
The experimental process involved the following steps:
1. Preparation of silk fibroin solution
A 4.0% w/v SF solution was incubated in a dry bath at 37 °C for 30 min.
2. Hydrogel formulation
Gelatin granules were added to the warmed SF solution to a final concentration of 1.5% w/v.
3. Mupirocin incorporation
MUP, pre-dissolved in propylene glycol, was introduced to achieve a final concentration of 2.0% w/v.
4. Gelation process
The mixture was cooled to room temperature, allowing gelation to occur. Bare SF hydrogels were prepared as controls without MUP addition.
Characterization revealed distinct FTIR signals confirming drug encapsulation. The hydrogel demonstrated 80% biodegradation within 24 h and reached a swelling equilibrium (ratio 2.5) within 2 h. Controlled release studies showed an initial burst of ~20% followed by sustained delivery of 60% over 72 h. Importantly, the MUP/SF-based hydrogel exhibited 100% antibacterial activity against Gram-positive bacteria, improved cell viability, reduced irritation scores, and promoted angiogenesis in CAM assays.
This stepwise approach demonstrates that MUP-loaded SF hydrogels provide a multifunctional platform with antibacterial, biocompatible, and pro-angiogenic properties, making them highly promising candidates for diabetic wound treatment.

Mupirocin for the Preparation of Core-Shell Nanofibrous Wound Dressings via Coaxial Electrospinning

Mirhaj, Marjan, et al. International Journal of Biological Macromolecules 253 (2023): 126700.

Mupirocin (Mup) is an effective topical antibiotic widely employed in the treatment of wound infections. However, its rapid release and short half-life limit clinical performance. To address this, a core-shell nanofibrous wound dressing composed of Pluronic-F127 (F127) as the drug-loaded core and pectin (Pec)-keratin (Kr) as the shell was fabricated using coaxial electrospinning. This architecture was compared to blended nanofibers of the same composition to evaluate drug release and wound healing efficacy.
The experimental process was as follows:
1. Solution preparation: F127 (20% w/v), Pec (8% w/v), and Kr (10% w/v) aqueous solutions were stirred individually for 24 h. F127-Pec solution (3:1) was prepared and further mixed with Kr to form an F127-Pec-Kr solution (2:1:1).
2. Drug incorporation: Mup powder (2% w/w) was added to the F127-Pec-Kr solution and stirred for 1 h for homogeneous dispersion.
3. Electrospinning (blended fibers): The polymeric solution was electrospun using a 0.6 mm needle tip at 0.5 mL/h feed rate, 15 kV potential, and 15 cm distance.
4. Electrospinning (core-shell fibers): F127-Mup solution served as the core and Kr-Pec solution as the shell in a coaxial setup (inner feed 0.5 mL/h, outer feed 2 mL/h).
5. Post-processing: Fibrous mats were cross-linked with 25% glutaraldehyde vapor for 24 h.
Core-shell nanofibers exhibited sustained Mup release (87.66% over 7 days), higher surface area (25.26 m²/g), and improved angiogenic and wound healing properties compared to blended fibers. This highlights the promise of Mup-loaded core-shell nanofibrous dressings for chronic wound management.